Direct Endoscopic Necrosectomy Market By Diagnosis (Abdominal Scan, Urine Test, Abdominal Biopsy) By Patient Disorder (Pancreatitis, Abdominal Pain, Abdominal Infection, Others) By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Market Overview

The Global Direct Endoscopic Necrosectomy Market size is expected to be worth around USD 369.8 Million by 2033 from USD 182.8 Million in 2023, growing at a CAGR of 7.3% during the forecast period from 2024 to 2033.

The Direct Endoscopic Necrosectomy (DEN) market encompasses the utilization of minimally invasive endoscopic techniques to remove necrotic, or dead, pancreatic tissue in patients suffering from necrotizing pancreatitis. This approach represents a significant advancement over traditional surgical methods, offering a less invasive option with potential benefits including reduced recovery times, lower risk of complications, and decreased postoperative discomfort.

The procedure is performed by inserting an endoscope through the mouth and into the pancreas, allowing for direct removal of dead tissue. The demand for DEN is driven by the increasing incidence of severe pancreatitis cases and a growing preference for minimally invasive medical procedures among both healthcare providers and patients.

Additionally, advancements in endoscopic technology and techniques are further propelling this market forward. Despite its benefits, the widespread adoption of DEN faces challenges such as the need for specialized training for healthcare providers and potential procedure-related risks. As medical technology continues to evolve, the DEN market is expected to expand, reflecting broader healthcare trends towards innovative, patient-friendly treatment options.

The most recent corrective technology to be used in the management of Walled-Off Necrosis (WON) is direct Endoscopic Necrosectomy (DEN). Through the gastric or duodenal divider, necrotic tissue can be drained and endoscopically debrided.

Sanctum had a greater WON assurance rate (88% versus 45%) than endoscopic seepage alone, highlighting the importance of debridement of semi-strong necrotic material. DEN is a method used in a pit or restricted space; as a result, when the procedure is completed, the opening that was created to allow access to the pit shuts on its own, without the assistance of anyone else.

Considering the use of endoscopic necrosectomy is controlled by both the imaging results and the patient’s indications. For example, depending on an individual patient, the necrotic assortment could be changed through the stomach or duodenum.

Key Takeaways

• Market Size: Global Direct Endoscopic Necrosectomy Market size is expected to be worth around USD 369.8 Million by 2033 from USD 182.8 Million in 2023.
• Market Growth: The market growing at a CAGR of 7.3% during the forecast period from 2024 to 2033.
• Diagnosis Analysis: The Direct Endoscopic Necrosectomy Market has seen significant growth, with abdominal scans dominating 58.4% of the market share in 2023.
• Patient Disorder Analysis: In 2023, the Direct Endoscopic Necrosectomy Market saw pancreatitis accounting for 50.19% of the market share.
• End-Use Analysis: In 2023, hospitals accounted for 67% of the Direct Endoscopic Necrosectomy Market share.
• Regional Analysis: In 2023, North America dominated the Direct Endoscopic Necrosectomy Market, holding a 39.5% market share.
• Rising Popularity: Ambulatory Surgical Centers and specialty clinics are gaining traction due to their cost-effectiveness and convenience for outpatient procedures.
• Technological Advancements: Continuous innovation in endoscopic technologies is enhancing the precision and safety of necrosectomy procedures.

Diagnosis Analysis

The Direct Endoscopic Necrosectomy Market has seen significant growth, with abdominal scans dominating 58.4% of the market share in 2023. This prevalence is due to the high accuracy and non-invasive nature of abdominal scans in diagnosing and monitoring pancreatic necrosis. The widespread adoption of advanced imaging technologies has driven market expansion, providing detailed visualization essential for effective treatment planning.

Urine tests and abdominal biopsies also play crucial roles in the diagnosis and management of pancreatic necrosis. Urine tests offer a less invasive diagnostic method, aiding in the detection of associated conditions and complications. Meanwhile, abdominal biopsies provide definitive histological confirmation, guiding therapeutic decisions. The integration of these diagnostic tools enhances the overall efficacy of direct endoscopic necrosectomy procedures.

As healthcare facilities continue to adopt these diagnostic methods, the market is expected to grow, driven by advancements in medical technology and increasing awareness about the benefits of early and accurate diagnosis. The combined use of abdominal scans, urine tests, and biopsies ensures comprehensive patient assessment and optimal treatment outcomes.

Patient Disorder Analysis

In 2023, the Direct Endoscopic Necrosectomy Market saw pancreatitis accounting for 50.19% of the market share. This significant portion is attributed to the rising incidence of severe pancreatitis cases that require advanced intervention. Pancreatitis often presents with acute abdominal pain, leading to further complications such as abdominal infections. The need for precise and minimally invasive treatment options has driven the adoption of direct endoscopic necrosectomy, which effectively addresses necrotic tissue within the pancreas.

Abdominal pain, a common symptom of pancreatitis, often prompts the need for thorough diagnostic and therapeutic procedures. Direct endoscopic necrosectomy provides a targeted approach to alleviate pain and treat infections, reducing the risk of further complications. The ability to directly access and remove necrotic tissue endoscopically minimizes recovery time and enhances patient outcomes.

Additionally, other conditions contributing to market growth include pancreatic abscesses and pseudocysts, which also benefit from this advanced procedure. The market is expected to continue its upward trajectory as awareness and accessibility to this treatment increase, supported by ongoing advancements in endoscopic technology.

End-User Analysis

In 2023, hospitals accounted for 67% of the Direct Endoscopic Necrosectomy Market share. This dominance is driven by the comprehensive facilities, advanced equipment, and specialized medical personnel available in hospital settings, making them the preferred choice for complex procedures like endoscopic necrosectomy. Hospitals provide the infrastructure necessary for high-risk interventions, ensuring patient safety and optimal outcomes.

Ambulatory Surgical Centers (ASCs) and specialty clinics are also significant contributors to the market. ASCs offer a cost-effective and efficient alternative for less complicated cases, with reduced waiting times and quicker patient turnover. These centers are becoming increasingly popular due to their convenience and ability to perform outpatient procedures with high success rates.

Specialty clinics, focusing on gastrointestinal and pancreatic disorders, provide targeted care with expertise in advanced endoscopic techniques. Their role in the market is growing as they offer personalized treatment plans and follow-up care, enhancing patient experiences and recovery rates.

The combined efforts of hospitals, ASCs, and specialty clinics are driving the expansion of the Direct Endoscopic Necrosectomy Market, ensuring comprehensive and accessible care for patients requiring this advanced procedure.

Market Segmentation

Diagnosis

• Abdominal Scan
• Urine Test
• Abdominal Biopsy

Patient Disorder

• Pancreatitis
• Abdominal Pain
• Abdominal Infection
• Others

End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Driver

The increasing incidence of pancreatic necrosis is a primary driver for the direct endoscopic necrosectomy market. With the global rise in acute pancreatitis cases, there’s a growing demand for minimally invasive treatment options like direct endoscopic necrosectomy.

This procedure offers a less invasive alternative to traditional surgical methods, leading to shorter recovery times and reduced morbidity rates. As healthcare providers seek to improve patient outcomes while minimizing healthcare costs, the demand for direct endoscopic necrosectomy is expected to continue to rise.

Trend

Advancements in endoscopic technology are driving a significant trend in the direct endoscopic necrosectomy market. Ongoing innovations in imaging modalities, instrument design, and procedural techniques are enhancing the efficacy and safety of direct endoscopic necrosectomy procedures.

High-definition imaging systems, specialized endoscopic tools, and advanced endoscopic platforms are enabling healthcare providers to perform more precise and efficient necrosectomy procedures. This trend towards technological innovation is expected to further accelerate the adoption of direct endoscopic necrosectomy in clinical practice.

Restraint

Limited access to specialized healthcare facilities presents a significant restraint to the direct endoscopic necrosectomy market. In regions with underdeveloped healthcare infrastructure or limited availability of specialized endoscopic centers, patients may face challenges accessing timely and appropriate care. The lack of access to skilled healthcare professionals trained in direct endoscopic necrosectomy techniques further exacerbates this restraint.

Addressing these barriers to access, such as through healthcare infrastructure development initiatives and training programs for healthcare professionals, will be essential for overcoming this restraint and expanding the reach of direct endoscopic necrosectomy services to underserved populations.

Opportunity

The growing preference for minimally invasive procedures represents a significant opportunity for the direct endoscopic necrosectomy market. As patients and healthcare providers increasingly prioritize treatments with reduced invasiveness, complications, and recovery times, the demand for direct endoscopic necrosectomy is expected to surge.

This shift in preference is driven by factors such as improved patient comfort, shorter hospital stays, and lower healthcare costs associated with minimally invasive procedures. By leveraging this opportunity and highlighting the benefits of direct endoscopic necrosectomy over traditional surgical approaches, healthcare providers can tap into a growing market segment seeking advanced minimally invasive treatment options for pancreatic necrosis.

Regional Analysis

In 2023, North America dominated the Direct Endoscopic Necrosectomy Market, holding a 39.5% market share. This significant presence is attributed to advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and increased awareness about minimally invasive procedures. The region’s leading medical institutions and skilled healthcare professionals contribute to the widespread utilization of direct endoscopic necrosectomy.

Additionally, supportive government policies and substantial investment in healthcare research and development further drive market growth in North America. This dominance underscores the region’s pivotal role in advancing endoscopic treatment options for pancreatic necrosis and related conditions.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Player Analysis

The Direct Endoscopic Necrosectomy Market features several key players who drive innovation and market growth. These companies focus on developing advanced endoscopic technologies and minimally invasive techniques to improve patient outcomes. They invest heavily in research and development, aiming to enhance the precision and safety of necrosectomy procedures. Strategic collaborations, mergers, and acquisitions are common among these market leaders, helping to expand their product portfolios and geographical reach.

Additionally, they prioritize training and education for healthcare professionals to ensure the effective use of their technologies. Their efforts collectively advance the standard of care in treating pancreatic necrosis.

Market Players

• Boston Scientific Corporation
• Cook Medical
• Medtronic plc
• Karl Storz SE & Co. KG
• Fujifilm Corporation
• PENTAX Medical
• Richard Wolf GmbH
• Karl Storz SE & Co. KG
• CONMED Corporation
• Other Key Players

Recent Development

• Boston Scientific Corporation – New Product Launch: In April 2023, Boston Scientific Corporation launched the “Exalt Model D,” a single-use duodenoscope. This innovative product aims to enhance patient safety by reducing the risk of cross-contamination and infections, featuring advanced imaging capabilities for precise and efficient direct endoscopic necrosectomy procedures.
• Cook Medical -: In June 2023, Cook Medical acquired a leading endoscopy solutions provider. This strategic move aims to expand Cook Medical’s product portfolio and strengthen its position in the direct endoscopic necrosectomy market, enhancing their capabilities in advanced endoscopic procedures.
• Medtronic plc – New Product Launch: In May 2023, Medtronic plc introduced the “StealthStation FlexENT,” an advanced navigation system for endoscopic procedures. This launch highlights Medtronic’s commitment to enhancing precision and safety in direct endoscopic necrosectomy, improving patient outcomes through innovative technology.
• Karl Storz SE & Co. KG – Merge: In March 2023, Karl Storz SE & Co. KG merged with a prominent medical imaging company. This merger aims to integrate advanced imaging technologies with Karl Storz’s endoscopic solutions, enhancing the effectiveness of direct endoscopic necrosectomy procedures.
• Fujifilm Corporation: In February 2023, Fujifilm Corporation launched the “ELUXEO Ultra,” an advanced endoscopic imaging system. This product offers superior visualization and diagnostic capabilities, supporting more accurate and efficient direct endoscopic necrosectomy, reflecting Fujifilm’s innovation in medical technology.

Report Scope